Pierre Duquette
Overview
Explore the profile of Pierre Duquette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
3354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari C, Lo Fermo S, et al.
Neurotherapeutics
. 2025 Feb;
22(2):e00552.
PMID: 39965993
Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated...
2.
Charest K, Potvin M, Brando E, Tremblay A, Roger E, Duquette P, et al.
Geriatr Psychol Neuropsychiatr Vieil
. 2025 Jan;
22(3):348-358.
PMID: 39840418
No abstract available.
3.
Desu H, Balthazard R, Daigneault A, Da Cal S, Klement W, Yu J, et al.
EBioMedicine
. 2025 Jan;
112:105559.
PMID: 39837012
Background: Immunosenescence is accelerated by chronic infectious and autoimmune diseases and could contribute to the pathobiology of multiple sclerosis (MS). How MS and disease-modifying therapies (DMTs) impact age-sensitive immune biomarkers...
4.
Yeh W, van der Walt A, Skibina O, Kalincik T, Alroughani R, Kermode A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200328.
PMID: 39442037
Background And Objectives: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS...
5.
Zertal A, Alami Marrouni K, Arbour N, Jutras-Aswad D, Pomey M, Rouleau I, et al.
Front Neurol
. 2024 Aug;
15:1440678.
PMID: 39114536
Background: Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system. More than 90,000 Canadians are affected; a cure is yet to be found. Available treatments...
6.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, et al.
Mult Scler
. 2024 Aug;
30(9):1163-1175.
PMID: 39087208
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS....
7.
Montembeault M, Farley R, Ouellet J, Brando E, Tremblay A, Charest K, et al.
J Neuropsychol
. 2024 Jul;
19(1):39-50.
PMID: 38982586
Theory of mind (ToM) deficits have been reported in persons with multiple sclerosis (pwMS). However, most studies have used pictures or written scenarios as stimuli without distinguishing between cognitive and...
8.
Lal A, Foong Y, Sanfilippo P, Spelman T, Rath L, Levitz D, et al.
J Neurol
. 2024 Jun;
271(9):5813-5824.
PMID: 38935148
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study...
9.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study
Dekeyser C, Hautekeete M, Cambron M, van Pesch V, Patti F, Kuhle J, et al.
J Neurol Neurosurg Psychiatry
. 2024 Apr;
95(11):1021-1031.
PMID: 38569872
Background: It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course. Methods: This large-scale cohort study included persons with MS with...
10.
Pomey M, Jutras-Aswad D, Paquette J, Saadi K, Taguemout M, Ikene D, et al.
Eur J Med Res
. 2024 Apr;
29(1):211.
PMID: 38561859
Context: Studies generally focus on one type of chronic condition and the effect of medical cannabis (MC) on symptoms; little is known about the perceptions and engagement of patients living...